首页 > 最新文献

Dermatologic Therapy最新文献

英文 中文
Topical Timolol in Dermatology: Applications and Advances 局部替马洛尔在皮肤病学:应用和进展
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-12-15 DOI: 10.1155/dth/5812080
Wang Yu, Wang Yue, Tang Shuanglu, Luo Yuanyuan, Huang Liping, Yu Qiuyue, Sun Jing, Tang Jing, Feng Yuebi, Mu Yunzu

Timolol, a nonselective β-adrenergic receptor blocker approved by the US Food and Drug Administration (FDA) in 1978 for glaucoma treatment, exhibits multiple pharmacological effects including vasoconstriction, promotion of epithelial healing, anti-inflammatory, and antioxidant properties. Although systemic administration is associated with significant adverse effects, its topical formulations have emerged as a research focus in dermatological therapy due to their superior safety profile and demonstrated efficacy. This article provides a systematic review of the current evidence-based advancements in the topical application of timolol in dermatology, aiming to offer a theoretical foundation for clinical practice.

替马洛尔是一种非选择性β-肾上腺素受体阻滞剂,于1978年被美国食品和药物管理局(FDA)批准用于青光眼治疗,具有多种药理作用,包括血管收缩、促进上皮愈合、抗炎和抗氧化特性。尽管全身给药与显著的不良反应有关,但其局部配方已成为皮肤病治疗的研究重点,因为它们具有优越的安全性和已证实的有效性。本文系统综述了目前噻洛尔在皮肤病学局部应用的循证进展,旨在为临床实践提供理论基础。
{"title":"Topical Timolol in Dermatology: Applications and Advances","authors":"Wang Yu,&nbsp;Wang Yue,&nbsp;Tang Shuanglu,&nbsp;Luo Yuanyuan,&nbsp;Huang Liping,&nbsp;Yu Qiuyue,&nbsp;Sun Jing,&nbsp;Tang Jing,&nbsp;Feng Yuebi,&nbsp;Mu Yunzu","doi":"10.1155/dth/5812080","DOIUrl":"https://doi.org/10.1155/dth/5812080","url":null,"abstract":"<p>Timolol, a nonselective <i>β</i>-adrenergic receptor blocker approved by the US Food and Drug Administration (FDA) in 1978 for glaucoma treatment, exhibits multiple pharmacological effects including vasoconstriction, promotion of epithelial healing, anti-inflammatory, and antioxidant properties. Although systemic administration is associated with significant adverse effects, its topical formulations have emerged as a research focus in dermatological therapy due to their superior safety profile and demonstrated efficacy. This article provides a systematic review of the current evidence-based advancements in the topical application of timolol in dermatology, aiming to offer a theoretical foundation for clinical practice.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5812080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations in Minimal Erythema Dose of 308-nm Excimer Laser Therapy Across Anatomical Sites in Asian Patients With Vitiligo 亚洲白癜风患者308 nm准分子激光治疗各解剖部位最小红斑剂量的变化
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-12-09 DOI: 10.1155/dth/2174848
Jiyuan Wu, Jingjing Wang, Meihua Chen, Ting Yao, Yan Liu, Chen Liu

Purpose

To investigate anatomical site-specific differences in the minimal erythema dose (MED) of 308-nm excimer laser therapy among Asian patients with vitiligo.

Methods

A retrospective analysis of MED data from 378 patients was conducted. Nonparametric tests were used to compare MED values across six anatomical sites and facial subregions, while Spearman correlation assessed influencing factors.

Results

MED values in lesional skin were significantly higher than in normal skin. Site-specific MED variations were observed, ranked from lowest to highest as follows: face, trunk, neck, scalp, extremities, and acral regions (hands/feet). Within facial subregions, periorbital and perioral mucosal areas exhibited 15%–25% lower MED values compared with other regions. Skin phototype, season, and age were independent predictors of MED (P < 0.05), whereas sex, family history, and lesion size showed no significant correlation.

Conclusion

MED values vary significantly across anatomical sites in Asian patients with vitiligo. Clinical phototherapy protocols should incorporate site-specific and skin type–adjusted dosing strategies, with particular attention to the lower MED thresholds of mucosal regions.

目的探讨亚洲白癜风患者308 nm准分子激光治疗最小红斑剂量(MED)的解剖部位特异性差异。方法对378例患者的MED资料进行回顾性分析。非参数检验用于比较6个解剖部位和面部亚区MED值,Spearman相关性评估影响因素。结果病变皮肤的MED值明显高于正常皮肤。观察到特定部位的MED变化,从低到高依次为:面部、躯干、颈部、头皮、四肢和肢端区域(手/脚)。在面部亚区中,眶周和口周粘膜区域的MED值比其他区域低15%-25%。皮肤光型、季节和年龄是MED的独立预测因子(P < 0.05),而性别、家族史和病变大小无显著相关性。结论亚洲白癜风患者各解剖部位MED值差异显著。临床光疗方案应结合部位特异性和皮肤类型调整剂量策略,特别注意粘膜区域较低的MED阈值。
{"title":"Variations in Minimal Erythema Dose of 308-nm Excimer Laser Therapy Across Anatomical Sites in Asian Patients With Vitiligo","authors":"Jiyuan Wu,&nbsp;Jingjing Wang,&nbsp;Meihua Chen,&nbsp;Ting Yao,&nbsp;Yan Liu,&nbsp;Chen Liu","doi":"10.1155/dth/2174848","DOIUrl":"https://doi.org/10.1155/dth/2174848","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To investigate anatomical site-specific differences in the minimal erythema dose (MED) of 308-nm excimer laser therapy among Asian patients with vitiligo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis of MED data from 378 patients was conducted. Nonparametric tests were used to compare MED values across six anatomical sites and facial subregions, while Spearman correlation assessed influencing factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MED values in lesional skin were significantly higher than in normal skin. Site-specific MED variations were observed, ranked from lowest to highest as follows: face, trunk, neck, scalp, extremities, and acral regions (hands/feet). Within facial subregions, periorbital and perioral mucosal areas exhibited 15%–25% lower MED values compared with other regions. Skin phototype, season, and age were independent predictors of MED (<i>P</i> &lt; 0.05), whereas sex, family history, and lesion size showed no significant correlation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MED values vary significantly across anatomical sites in Asian patients with vitiligo. Clinical phototherapy protocols should incorporate site-specific and skin type–adjusted dosing strategies, with particular attention to the lower MED thresholds of mucosal regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2174848","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): A Retrospective Study From a Tertiary Care Hospital 对称性药物相关性三叉间和弯曲性湿疹(SDRIFE)的诊断特征:来自三级医院的回顾性研究
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-12-09 DOI: 10.1155/dth/1433440
Luis Carrasco-Gómez, Alba Lecumberri, José María Renilla-Arroyo, Belén de la Hoz-Caballer, Laura Díaz-Montalvo, Javier Martínez-Botas, Alicia Barra-Castro, Montserrat Fernández-Guarino

Background

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare hypersensitivity reaction characterized by symmetric erythematous rashes in intertriginous regions, triggered by systemic drugs. Although self-limiting, SDRIFE can significantly impact quality of life, requiring accurate diagnosis and management.

Objectives

This study aimed to describe the clinical characteristics, diagnostic approaches, and implicated pharmacological agents in the largest reported SDRIFE series, providing insights to improve diagnosis and treatment.

Materials and Methods

A retrospective observational study was conducted between 2018 and 2024. Data on demographics, clinical features, implicated drugs, and diagnostic tests—including drug provocation tests (DPTs), lymphocyte transformation tests (LTTs), and intradermal tests—were analyzed.

Results

Among 41 patients, the mean age was 66.6 years, with frequent polypharmacy complicating diagnosis. Beta-lactam antibiotics and iodinated contrast agents were the most implicated drugs. Nine previously unreported drugs were identified as triggers. DPT confirmed causality in six cases, and LTT aided in three complex cases. Avoidance of the suspected drug or pharmacological group was the main therapeutic measure.

Conclusions

Systematic medication reviews and standardized protocols are crucial for SDRIFE diagnosis. DPT remains the gold standard, while LTT adds value in complex cases, avoiding unnecessary drug restrictions and expanding therapeutic options.

背景:对称性药物相关性三叉间屈性疹(SDRIFE)是一种罕见的过敏反应,其特征是三叉间区对称性红斑皮疹,由全身药物引发。虽然是自限性的,但SDRIFE可以显著影响生活质量,需要准确的诊断和管理。本研究旨在描述最大的SDRIFE系列报道的临床特征、诊断方法和涉及的药物,为提高诊断和治疗提供见解。材料与方法2018 - 2024年进行回顾性观察研究。分析了人口统计学、临床特征、相关药物和诊断试验(包括药物激发试验(DPTs)、淋巴细胞转化试验(LTTs)和皮内试验)的数据。结果41例患者平均年龄66.6岁,多药并发诊断。β -内酰胺类抗生素和碘造影剂是最受影响的药物。九种以前未报告的药物被确定为触发因素。DPT在6例中证实了因果关系,LTT在3例复杂病例中起辅助作用。避免使用可疑药物或药物组是主要的治疗措施。结论系统的药物评价和标准化的治疗方案对SDRIFE的诊断至关重要。DPT仍然是金标准,而LTT在复杂病例中增加了价值,避免了不必要的药物限制并扩大了治疗选择。
{"title":"Diagnostic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): A Retrospective Study From a Tertiary Care Hospital","authors":"Luis Carrasco-Gómez,&nbsp;Alba Lecumberri,&nbsp;José María Renilla-Arroyo,&nbsp;Belén de la Hoz-Caballer,&nbsp;Laura Díaz-Montalvo,&nbsp;Javier Martínez-Botas,&nbsp;Alicia Barra-Castro,&nbsp;Montserrat Fernández-Guarino","doi":"10.1155/dth/1433440","DOIUrl":"https://doi.org/10.1155/dth/1433440","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare hypersensitivity reaction characterized by symmetric erythematous rashes in intertriginous regions, triggered by systemic drugs. Although self-limiting, SDRIFE can significantly impact quality of life, requiring accurate diagnosis and management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to describe the clinical characteristics, diagnostic approaches, and implicated pharmacological agents in the largest reported SDRIFE series, providing insights to improve diagnosis and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A retrospective observational study was conducted between 2018 and 2024. Data on demographics, clinical features, implicated drugs, and diagnostic tests—including drug provocation tests (DPTs), lymphocyte transformation tests (LTTs), and intradermal tests—were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 41 patients, the mean age was 66.6 years, with frequent polypharmacy complicating diagnosis. Beta-lactam antibiotics and iodinated contrast agents were the most implicated drugs. Nine previously unreported drugs were identified as triggers. DPT confirmed causality in six cases, and LTT aided in three complex cases. Avoidance of the suspected drug or pharmacological group was the main therapeutic measure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Systematic medication reviews and standardized protocols are crucial for SDRIFE diagnosis. DPT remains the gold standard, while LTT adds value in complex cases, avoiding unnecessary drug restrictions and expanding therapeutic options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1433440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Orienting Skin Grafts Parallel to Skin Tension Lines and Color Matching on Quality of Life in Patients With Basal Cell Carcinoma (Skin Types II–IV) 平行皮肤张力线定向植皮及配色对基底细胞癌(II-IV型皮肤)患者生活质量的影响
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-12-07 DOI: 10.1155/dth/9105783
Hilayda Karakök Kışla, Mustafa Gundogdu, Ceren Efe Sayın

Background

While the importance of skin tension lines in planning excisions is well-documented, its importance in planning grafts is less investigated. This study investigates the effect of orienting grafts along with skin tension lines on quality of life.

Methods

Patients with basal cell carcinoma and treated with either no specific attention for orientation (Group 1, n = 40) or skin tension line–oriented grafting (Group 2, n = 31) were evaluated by Skin Cancer Quality of Life Impact Tool (SCQOLIT) and the Dermatology Quality of Life Index (DLQI) 3 months after surgery. Cosmetic outcome was evaluated by a visual analog scale (VAS).

Results

Seventy-one patients were included (34 males [47.9%] and 37 females [52.1%]; mean age 66.55 ± 9.43). The mean VAS score was 5.64 ± 0.94 for Group 1 and 6.13 ± 0.99 for Group 2. The mean DLQI score was 1 (0–22) for both groups, and the mean SCQOLIT scores were 10 (0–27) for Group 1 and 10 (0–32) for Group 2. While VAS scores significantly differed between groups (p < 0.05), no difference in quality of life was observed.

Conclusion

Tension line–oriented grafting yielded better cosmetic outcomes without demonstrating superiority in terms of quality of life.

Trial Registration: ClinicalTrials.gov identifier: NCT06894056.

背景:虽然皮张力线在计划切除中的重要性是有据可查的,但它在计划移植物中的重要性却很少被研究。本研究探讨沿皮肤张力线定向移植物对生活质量的影响。方法对基底细胞癌患者进行无定向治疗(1组,n = 40)和皮肤张力线定向移植(2组,n = 31),术后3个月采用皮肤癌生活质量影响工具(SCQOLIT)和皮肤生活质量指数(DLQI)进行评价。采用视觉模拟量表(VAS)评价美容效果。结果纳入71例患者,其中男性34例(47.9%),女性37例(52.1%),平均年龄66.55±9.43岁。VAS评分1组(5.64±0.94),2组(6.13±0.99)。两组患者DLQI平均评分为1 (0-22),SCQOLIT平均评分为10 (0-27),SCQOLIT平均评分为10(0-32)。VAS评分组间差异有统计学意义(p < 0.05),生活质量组间差异无统计学意义。结论张力线植入术具有较好的美容效果,但在生活质量方面无明显优势。试验注册:ClinicalTrials.gov标识符:NCT06894056。
{"title":"Efficacy of Orienting Skin Grafts Parallel to Skin Tension Lines and Color Matching on Quality of Life in Patients With Basal Cell Carcinoma (Skin Types II–IV)","authors":"Hilayda Karakök Kışla,&nbsp;Mustafa Gundogdu,&nbsp;Ceren Efe Sayın","doi":"10.1155/dth/9105783","DOIUrl":"https://doi.org/10.1155/dth/9105783","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While the importance of skin tension lines in planning excisions is well-documented, its importance in planning grafts is less investigated. This study investigates the effect of orienting grafts along with skin tension lines on quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with basal cell carcinoma and treated with either no specific attention for orientation (Group 1, <i>n</i> = 40) or skin tension line–oriented grafting (Group 2, <i>n</i> = 31) were evaluated by Skin Cancer Quality of Life Impact Tool (SCQOLIT) and the Dermatology Quality of Life Index (DLQI) 3 months after surgery. Cosmetic outcome was evaluated by a visual analog scale (VAS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-one patients were included (34 males [47.9%] and 37 females [52.1%]; mean age 66.55 ± 9.43). The mean VAS score was 5.64 ± 0.94 for Group 1 and 6.13 ± 0.99 for Group 2. The mean DLQI score was 1 (0–22) for both groups, and the mean SCQOLIT scores were 10 (0–27) for Group 1 and 10 (0–32) for Group 2. While VAS scores significantly differed between groups (<i>p</i> &lt; 0.05), no difference in quality of life was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Tension line–oriented grafting yielded better cosmetic outcomes without demonstrating superiority in terms of quality of life.</p>\u0000 \u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT06894056.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9105783","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Efficacy and Safety of Nonablative 1550-nm Fractional Laser for Facial Syringoma: A Case Series Study 非烧蚀性1550nm分形激光治疗面部鼻窦瘤的疗效和安全性评价:一个病例系列研究
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-12-05 DOI: 10.1155/dth/6337375
Tae Min Kim, So young Kwon, Soyun Cho

Background

Syringoma has been known to recur following conventional treatments like cryotherapy and CO2 laser. The risk of side effects, such as erythema, edema, scarring, and postinflammatory hyperpigmentation, results in unsatisfactory outcomes.

Objective

To evaluate the efficacy and safety of 1550-nm nonablative fractional laser for treating syringoma.

Methods

We retrospectively analyzed the medical records of syringoma patients who underwent 1550-nm fractional laser treatment. Two blinded dermatologists assessed the treatment efficacy of syringoma based on randomized clinical photographs before and after treatment, using the Periorbital Syringoma Severity Index (PSSI) score and a Global Improvement Scale. Additionally, the types and duration of any side effects occurring after the treatment were evaluated.

Results

A total of 8 patients underwent 22 sessions of 1550-nm fractional laser treatment, averaging 2.75 sessions per patient (median, 2 sessions; range, 1–6 sessions). The female-to-male ratio was 7 : 1, with 3 patients (37.5%) having prior experience with CO2 laser. The pretreatment PSSI score improved from 4.00 to 2.88 after treatment (p = 0.03). Notably, 2 patients (25.0%) showed marked improvement, and 3 patients (37.5%) exhibited a moderate response. There was a strong correlation between the number of sessions and both the Global Improvement Scale (r = 0.783, p = 0.02) and PSSI score reduction (r = 0.619, p = 0.10). No scarring or dyspigmentation was observed postlaser treatment, and transient edema in 3 patients resolved on average after 13.7 days (median, 7 days).

Conclusion

Although this study is limited by its retrospective design and small sample size, its findings underscore the clinical efficacy of the 1550-nm nonablative fractional laser for the treatment of syringoma. Considering its nonablative nature and short downtime, the 1550-nm fractional laser is a safe and effective treatment alternative.

背景:已知在常规治疗如冷冻治疗和CO2激光治疗后会复发。副作用的风险,如红斑、水肿、疤痕和炎症后色素沉着,导致不满意的结果。目的评价1550 nm非烧蚀性分束激光治疗丁香瘤的疗效和安全性。方法回顾性分析接受1550 nm分次激光治疗的患者病历。两名盲法皮肤科医生根据治疗前后的随机临床照片,使用眶周针管瘤严重程度指数(PSSI)评分和全球改善量表评估针管瘤的治疗效果。此外,还评估了治疗后发生的任何副作用的类型和持续时间。结果8例患者共接受了22次1550 nm分次激光治疗,平均每例2.75次(中位数为2次,范围为1-6次)。男女比例为7:1,有3例(37.5%)患者有CO2激光治疗经验。治疗后PSSI评分由4.00分提高至2.88分(p = 0.03)。值得注意的是,2例(25.0%)患者有明显改善,3例(37.5%)患者有中度缓解。治疗次数与整体改善量表(r = 0.783, p = 0.02)和PSSI评分降低(r = 0.619, p = 0.10)之间存在很强的相关性。激光治疗后无瘢痕形成或色素沉着,3例患者短暂性水肿平均在13.7天(中位7天)后消退。结论虽然本研究的局限性在于其回顾性设计和小样本量,但其结果强调了1550 nm非烧成性分数激光治疗耳膜瘤的临床疗效。考虑到其非烧蚀性和短停机时间,1550纳米分数激光是一种安全有效的治疗选择。
{"title":"Evaluation of the Efficacy and Safety of Nonablative 1550-nm Fractional Laser for Facial Syringoma: A Case Series Study","authors":"Tae Min Kim,&nbsp;So young Kwon,&nbsp;Soyun Cho","doi":"10.1155/dth/6337375","DOIUrl":"https://doi.org/10.1155/dth/6337375","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Syringoma has been known to recur following conventional treatments like cryotherapy and CO<sub>2</sub> laser. The risk of side effects, such as erythema, edema, scarring, and postinflammatory hyperpigmentation, results in unsatisfactory outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the efficacy and safety of 1550-nm nonablative fractional laser for treating syringoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed the medical records of syringoma patients who underwent 1550-nm fractional laser treatment. Two blinded dermatologists assessed the treatment efficacy of syringoma based on randomized clinical photographs before and after treatment, using the Periorbital Syringoma Severity Index (PSSI) score and a Global Improvement Scale. Additionally, the types and duration of any side effects occurring after the treatment were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 8 patients underwent 22 sessions of 1550-nm fractional laser treatment, averaging 2.75 sessions per patient (median, 2 sessions; range, 1–6 sessions). The female-to-male ratio was 7 : 1, with 3 patients (37.5%) having prior experience with CO<sub>2</sub> laser. The pretreatment PSSI score improved from 4.00 to 2.88 after treatment (<i>p</i> = 0.03). Notably, 2 patients (25.0%) showed marked improvement, and 3 patients (37.5%) exhibited a moderate response. There was a strong correlation between the number of sessions and both the Global Improvement Scale (<i>r</i> = 0.783, <i>p</i> = 0.02) and PSSI score reduction (<i>r</i> = 0.619, <i>p</i> = 0.10). No scarring or dyspigmentation was observed postlaser treatment, and transient edema in 3 patients resolved on average after 13.7 days (median, 7 days).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although this study is limited by its retrospective design and small sample size, its findings underscore the clinical efficacy of the 1550-nm nonablative fractional laser for the treatment of syringoma. Considering its nonablative nature and short downtime, the 1550-nm fractional laser is a safe and effective treatment alternative.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6337375","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic Effects of Fractional CO2 Laser and Recombinant Humanized Type III Collagen (rhCol III) in Atrophic Acne Scar Treatment: Activation of MAPK Pathway and Enhanced Collagen Remodeling CO2激光和重组人源化III型胶原(rhCol III)在萎缩性痤疮瘢痕治疗中的协同作用:活化MAPK通路和增强胶原重塑
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-12-05 DOI: 10.1155/dth/6736692
Li Gu, Jing Wang, Rong Guo, Zhinan Shi, Zhiyi Xu, Shu Zhou, Jingting Zhao, Liqun Gu, Bingrong Zhou, Hui Hua
<div> <section> <h3> Background</h3> <p>Fractional CO<sub>2</sub> laser (FCL) is widely used for resurfacing the skin with atrophic acne scars. This study aims to explore the synergistic efficacy of recombinant humanized type III collagen (rhCol III) on FCL in treating atrophic acne scars.</p> </section> <section> <h3> Methods</h3> <p>A total of 20 patients with facial atrophic acne scars from two medical institutions were treated with a single session of full-face FCL. One month post-FCL, they were randomly assigned to the FCL + rhCol III group and FCL + NC group, with 10 cases per group. Patients in the FCL + rhCol III group received dermal injections with 4 mg of rhCol III dissolved in 1.2 mL of saline on one side of the face, and those in the FCL + NC group were similarly injected with the same amount of saline. Dermal injections were performed three times, with an interval of 4 weeks. Therapeutic efficacy was assessed using the Echelle d’évaluation clinique des cicatrices d’acné (ECCA) grading scale and the Global Scarring Grading System (GSS). Human dermal fibroblasts (HDFs) were cultured in vitro, and induced with FCL and rhCol III. Immunofluorescence was utilized to detect the expression of type I and III collagens. RNA-sequencing (RNA-seq) identified differentially expressed genes (DEGs) in HDFs induced with FCL combined with rhCol III.</p> </section> <section> <h3> Results</h3> <p>A total of 18 eligible patients were enrolled and followed up. Post-treatment, patients in the FCL + rhCol III group were graded with a significantly lower ECCA score (77.50 ± 15.07 vs. 106.1 ± 21.25, <i>p</i> < 0.05), but a higher scar improvement rate (40.23% ± 13.23% vs. 23.26% ± 19.69%, <i>p</i> < 0.05) than those in the FCL + NC group. Classified by the type of acne scars, patients with boxcar and icepick acne scars significantly benefited more from FCL combined with rhCol III than those in the FCL + NC group and showed a significantly reduced ECCA score and an increased scar improvement rate (<i>p</i> < 0.05). Similarly, patients in the FCL + rhCol III group also exhibited significantly a lower GSS score (7.75 ± 1.75 vs. 10.00 ± 2.33, <i>p</i> < 0.05) and a higher scar improvement rate (43.30% ± 10.49% vs. 25.59% ± 18.34%, <i>p</i> < 0.05). In vitro experiments showed that the induction of FCL combined with rhCol III significantly upregulated type I and III collagens in HDFs. RNA-seq unmasked that MAPK signaling pathway was activated in HDFs induced with FCL combined with rhCol III.</p> </section> <section> <h3> Conclusion</h3> <p>FCL combined with rhCol
CO2激光(FCL)广泛应用于萎缩性痤疮疤痕的皮肤表面修复。本研究旨在探讨重组人源化III型胶原(rhCol III)对FCL治疗萎缩性痤疮疤痕的协同作用。方法对2家医疗机构收治的20例面部萎缩性痤疮疤痕患者,采用一次全脸FCL治疗。术后1个月,随机分为FCL + rhCol III组和FCL + NC组,每组10例。FCL + rhCol III组患者接受皮肤注射,将4 mg rhCol III溶解于一侧面部1.2 mL生理盐水中,FCL + NC组同样注射等量生理盐水。真皮注射3次,间隔4周。采用瘢痕形成阶梯(ECCA)分级量表和全球瘢痕形成分级系统(GSS)评估治疗效果。体外培养人真皮成纤维细胞(HDFs),用FCL和rhCol III诱导。采用免疫荧光法检测I型和III型胶原蛋白的表达。rna测序(RNA-seq)鉴定了FCL联合rhCol III诱导的HDFs中的差异表达基因(DEGs)。结果共纳入18例符合条件的患者并进行随访。治疗后,FCL + rhCol III组患者的ECCA评分明显低于FCL + NC组(77.50±15.07比106.1±21.25,p < 0.05),但瘢痕改好率高于FCL + NC组(40.23%±13.23%比23.26%±19.69%,p < 0.05)。按痤疮疤痕类型分类,FCL联合rhCol III组与FCL + NC组相比,盒型和冰锥型痤疮疤痕患者获益更大,ECCA评分显著降低,疤痕改好率显著提高(p < 0.05)。同样,FCL + rhCol III组患者GSS评分也显著降低(7.75±1.75比10.00±2.33,p < 0.05),瘢痕改良率显著提高(43.30%±10.49%比25.59%±18.34%,p < 0.05)。体外实验表明,FCL联合rhCol III诱导可显著上调HDFs中的I型和III型胶原。RNA-seq结果显示,FCL联合rhCol III诱导的HDFs中,MAPK信号通路被激活。结论FCL联合rhCol III可通过激活MAPK通路有效减轻面部萎缩性痤疮疤痕。
{"title":"Synergistic Effects of Fractional CO2 Laser and Recombinant Humanized Type III Collagen (rhCol III) in Atrophic Acne Scar Treatment: Activation of MAPK Pathway and Enhanced Collagen Remodeling","authors":"Li Gu,&nbsp;Jing Wang,&nbsp;Rong Guo,&nbsp;Zhinan Shi,&nbsp;Zhiyi Xu,&nbsp;Shu Zhou,&nbsp;Jingting Zhao,&nbsp;Liqun Gu,&nbsp;Bingrong Zhou,&nbsp;Hui Hua","doi":"10.1155/dth/6736692","DOIUrl":"https://doi.org/10.1155/dth/6736692","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Fractional CO&lt;sub&gt;2&lt;/sub&gt; laser (FCL) is widely used for resurfacing the skin with atrophic acne scars. This study aims to explore the synergistic efficacy of recombinant humanized type III collagen (rhCol III) on FCL in treating atrophic acne scars.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 20 patients with facial atrophic acne scars from two medical institutions were treated with a single session of full-face FCL. One month post-FCL, they were randomly assigned to the FCL + rhCol III group and FCL + NC group, with 10 cases per group. Patients in the FCL + rhCol III group received dermal injections with 4 mg of rhCol III dissolved in 1.2 mL of saline on one side of the face, and those in the FCL + NC group were similarly injected with the same amount of saline. Dermal injections were performed three times, with an interval of 4 weeks. Therapeutic efficacy was assessed using the Echelle d’évaluation clinique des cicatrices d’acné (ECCA) grading scale and the Global Scarring Grading System (GSS). Human dermal fibroblasts (HDFs) were cultured in vitro, and induced with FCL and rhCol III. Immunofluorescence was utilized to detect the expression of type I and III collagens. RNA-sequencing (RNA-seq) identified differentially expressed genes (DEGs) in HDFs induced with FCL combined with rhCol III.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 18 eligible patients were enrolled and followed up. Post-treatment, patients in the FCL + rhCol III group were graded with a significantly lower ECCA score (77.50 ± 15.07 vs. 106.1 ± 21.25, &lt;i&gt;p&lt;/i&gt; &lt; 0.05), but a higher scar improvement rate (40.23% ± 13.23% vs. 23.26% ± 19.69%, &lt;i&gt;p&lt;/i&gt; &lt; 0.05) than those in the FCL + NC group. Classified by the type of acne scars, patients with boxcar and icepick acne scars significantly benefited more from FCL combined with rhCol III than those in the FCL + NC group and showed a significantly reduced ECCA score and an increased scar improvement rate (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). Similarly, patients in the FCL + rhCol III group also exhibited significantly a lower GSS score (7.75 ± 1.75 vs. 10.00 ± 2.33, &lt;i&gt;p&lt;/i&gt; &lt; 0.05) and a higher scar improvement rate (43.30% ± 10.49% vs. 25.59% ± 18.34%, &lt;i&gt;p&lt;/i&gt; &lt; 0.05). In vitro experiments showed that the induction of FCL combined with rhCol III significantly upregulated type I and III collagens in HDFs. RNA-seq unmasked that MAPK signaling pathway was activated in HDFs induced with FCL combined with rhCol III.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;FCL combined with rhCol","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6736692","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National, Regional, and Global Epidemiology of Alopecia Areata: A Systematic Analysis Based on Modeling Study 国家、地区和全球斑秃流行病学:基于模型研究的系统分析
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-11-26 DOI: 10.1155/dth/6716671
Shuntong Kang, Dingyao Zhang, Yaqing Huang, Jingru Tian, Qianjin Lu

Background

Alopecia areata (AA) is a prevalent nonscarring hair loss disease affecting the scalp and body hair. However, previous studies have reported conflicting findings regarding its epidemiology. We aimed to quantify the global, regional, and country-specific estimates of AA epidemiology.

Methods

We conducted a comprehensive systematic review of published studies reporting on the incidence and prevalence of AA. We searched four electronic databases from January 1, 1992 to October 20, 2023: PubMed, Embase, Web of Science, and China National Knowledge Infrastructure. A Bayesian hierarchical linear mixed model was employed to determine the epidemiological estimates, accounting for variations in regions, diagnostic types, and age groups.

Results

73 studies met the inclusion criteria. The incidence varied across different geographical locations and age strata. The overall point prevalence and diagnosed population of AA were estimated at 1.93% (0.17%–5.91%) and 15.05 million people, respectively. The United Kingdom, Saudi Arabia, Iraq, and Egypt exhibited the highest prevalence. Globally, approximately 10.29 million adults and 4.76 million children had AA, with a prevalence of 1.98% (0.17%–6.07%) for adults and 1.83% (0.16%–5.58%) for children. Women were more likely to suffer from it. The global prevalence in females was 2.25% (0.20%–7.03%), affecting 8.69 million individuals, whereas for males, the estimates were 1.62% (0.14%–4.80%), impacting 6.36 million individuals. Variations in the epidemiological results might also stem from the chosen method of prevalence estimation.

Conclusion

Epidemiological data for AA were absent in 89.1% of countries globally. The epidemiology varied across gender and age groups and was unevenly distributed among geographical regions.

斑秃(AA)是一种常见的影响头皮和体毛的非瘢痕性脱发疾病。然而,之前的研究报告了关于其流行病学的相互矛盾的发现。我们的目的是量化AA流行病学的全球、区域和国家特异性估计。方法我们对已发表的有关AA发病率和患病率的研究进行了全面系统的综述。检索了1992年1月1日至2023年10月20日的4个电子数据库:PubMed、Embase、Web of Science和China National Knowledge Infrastructure。采用贝叶斯层次线性混合模型确定流行病学估计,考虑到地区、诊断类型和年龄组的差异。结果73项研究符合纳入标准。不同地理位置和年龄层的发病率不同。AA总点位患病率为1.93%(0.17% ~ 5.91%),诊断人群为1505万人。英国、沙特阿拉伯、伊拉克和埃及的患病率最高。全球约有1029万成人和476万儿童患有AA,其中成人患病率为1.98%(0.17%-6.07%),儿童患病率为1.83%(0.16%-5.58%)。女性更容易患此病。全球女性患病率为2.25%(0.20% ~ 7.03%),影响869万人;全球男性患病率为1.62%(0.14% ~ 4.80%),影响636万人。流行病学结果的差异也可能源于所选择的流行率估计方法。结论全球89.1%的国家缺乏AA流行病学资料。流行病学在性别和年龄组之间存在差异,在地理区域之间分布不均匀。
{"title":"National, Regional, and Global Epidemiology of Alopecia Areata: A Systematic Analysis Based on Modeling Study","authors":"Shuntong Kang,&nbsp;Dingyao Zhang,&nbsp;Yaqing Huang,&nbsp;Jingru Tian,&nbsp;Qianjin Lu","doi":"10.1155/dth/6716671","DOIUrl":"https://doi.org/10.1155/dth/6716671","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Alopecia areata (AA) is a prevalent nonscarring hair loss disease affecting the scalp and body hair. However, previous studies have reported conflicting findings regarding its epidemiology. We aimed to quantify the global, regional, and country-specific estimates of AA epidemiology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive systematic review of published studies reporting on the incidence and prevalence of AA. We searched four electronic databases from January 1, 1992 to October 20, 2023: PubMed, Embase, Web of Science, and China National Knowledge Infrastructure. A Bayesian hierarchical linear mixed model was employed to determine the epidemiological estimates, accounting for variations in regions, diagnostic types, and age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>73 studies met the inclusion criteria. The incidence varied across different geographical locations and age strata. The overall point prevalence and diagnosed population of AA were estimated at 1.93% (0.17%–5.91%) and 15.05 million people, respectively. The United Kingdom, Saudi Arabia, Iraq, and Egypt exhibited the highest prevalence. Globally, approximately 10.29 million adults and 4.76 million children had AA, with a prevalence of 1.98% (0.17%–6.07%) for adults and 1.83% (0.16%–5.58%) for children. Women were more likely to suffer from it. The global prevalence in females was 2.25% (0.20%–7.03%), affecting 8.69 million individuals, whereas for males, the estimates were 1.62% (0.14%–4.80%), impacting 6.36 million individuals. Variations in the epidemiological results might also stem from the chosen method of prevalence estimation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Epidemiological data for AA were absent in 89.1% of countries globally. The epidemiology varied across gender and age groups and was unevenly distributed among geographical regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6716671","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder (PCSM-LPD): Dermoscopic Clues to Address Its Diagnosis and Their Interobserver Reliability 原发性皮肤CD4+小/中型t细胞淋巴增生性疾病(PCSM-LPD):皮肤镜线索解决其诊断及其观察者之间的可靠性
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-11-25 DOI: 10.1155/dth/9975973
Corrado Zengarini, Giulia Bandini, Marco Adriano Chessa, Alba Guglielmo, Martina Mussi, Vieri Grandi, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini, Alessandro Pileri

Background

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-LPD) is a rare lymphoid proliferation whose dermoscopic features are poorly defined, making diagnosis challenging. This study aims to identify the most common dermoscopic features of PCSM-LPD, assess their diagnostic accuracy, and evaluate interobserver reproducibility.

Methods

We conducted a retrospective study in a referral clinic, including patients with histologically confirmed PCSM-LPD and a control group of various cutaneous lymphomas. Two experienced dermatologists independently reviewed dermoscopic images. Key dermoscopic features were identified and compared between the groups. Interoperator reproducibility was measured using Cohen’s Kappa. Diagnostic accuracy and agreement were the primary outcome measures.

Results

We analysed 18 PCSM-LPD cases and 18 controls. Serpentine vessels were the most common feature in PCSM-LPD, with a sensitivity of 100% and specificity of 76.5%. Keratin plugs had a sensitivity of 88.9% and a specificity of 77.8%. A yellow-orange background was also significant, with 100% sensitivity and 77.8% specificity. Interoperator agreement showed low to moderate Kappa values, with better agreement for vessel presence and keratin plugs but lower for vessel type and distribution.

Discussion

Serpentine vessels, keratin plugs, and yellow-orange background characteristics were found to be very sensitive and specific; however, their usability needs to be contextualised for diagnosing PCSM-LPD. Finally, despite high diagnostic accuracy, the interobserver agreement seems inconsistent, highlighting the need for standardised training. Further studies are necessary to validate these findings and improve diagnostic consistency in clinical practice.

原发性皮肤CD4+小/中型t细胞淋巴细胞增生性疾病(PCSM-LPD)是一种罕见的淋巴细胞增生,其皮肤镜特征不明确,使诊断具有挑战性。本研究旨在确定PCSM-LPD最常见的皮肤镜特征,评估其诊断准确性,并评估观察者间的可重复性。方法我们在一家转诊诊所进行了回顾性研究,包括组织学证实的PCSM-LPD患者和对照组的各种皮肤淋巴瘤。两位经验丰富的皮肤科医生独立审查了皮肤镜图像。确定各组之间的主要皮肤镜特征并进行比较。使用Cohen 's Kappa测量操作者间的重复性。诊断的准确性和一致性是主要的结局指标。结果我们分析了18例PCSM-LPD病例和18例对照组。蛇形血管是PCSM-LPD最常见的特征,其敏感性为100%,特异性为76.5%。角蛋白塞的敏感性为88.9%,特异性为77.8%。黄橙色背景也很重要,具有100%的敏感性和77.8%的特异性。操作者之间的一致性显示Kappa值低至中等,对血管存在和角蛋白塞的一致性较好,但对血管类型和分布的一致性较低。蛇形血管、角蛋白塞和黄橙色背景特征是非常敏感和特异性的;然而,他们的可用性需要在诊断PCSM-LPD的背景下进行分析。最后,尽管诊断准确性很高,但观察者之间的共识似乎不一致,这突出了标准化培训的必要性。需要进一步的研究来验证这些发现并提高临床实践中的诊断一致性。
{"title":"Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder (PCSM-LPD): Dermoscopic Clues to Address Its Diagnosis and Their Interobserver Reliability","authors":"Corrado Zengarini,&nbsp;Giulia Bandini,&nbsp;Marco Adriano Chessa,&nbsp;Alba Guglielmo,&nbsp;Martina Mussi,&nbsp;Vieri Grandi,&nbsp;Claudio Agostinelli,&nbsp;Elena Sabattini,&nbsp;Bianca Maria Piraccini,&nbsp;Alessandro Pileri","doi":"10.1155/dth/9975973","DOIUrl":"https://doi.org/10.1155/dth/9975973","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-LPD) is a rare lymphoid proliferation whose dermoscopic features are poorly defined, making diagnosis challenging. This study aims to identify the most common dermoscopic features of PCSM-LPD, assess their diagnostic accuracy, and evaluate interobserver reproducibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective study in a referral clinic, including patients with histologically confirmed PCSM-LPD and a control group of various cutaneous lymphomas. Two experienced dermatologists independently reviewed dermoscopic images. Key dermoscopic features were identified and compared between the groups. Interoperator reproducibility was measured using Cohen’s Kappa. Diagnostic accuracy and agreement were the primary outcome measures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We analysed 18 PCSM-LPD cases and 18 controls. Serpentine vessels were the most common feature in PCSM-LPD, with a sensitivity of 100% and specificity of 76.5%. Keratin plugs had a sensitivity of 88.9% and a specificity of 77.8%. A yellow-orange background was also significant, with 100% sensitivity and 77.8% specificity. Interoperator agreement showed low to moderate Kappa values, with better agreement for vessel presence and keratin plugs but lower for vessel type and distribution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Serpentine vessels, keratin plugs, and yellow-orange background characteristics were found to be very sensitive and specific; however, their usability needs to be contextualised for diagnosing PCSM-LPD. Finally, despite high diagnostic accuracy, the interobserver agreement seems inconsistent, highlighting the need for standardised training. Further studies are necessary to validate these findings and improve diagnostic consistency in clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9975973","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence and Clinical Characteristics of PHACE Syndrome in Facial Segmental Hemangiomas: A Single-Center Retrospective Study 面部节段性血管瘤中PHACE综合征的患病率和临床特征:一项单中心回顾性研究
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-11-25 DOI: 10.1155/dth/4078903
Jingjing Sun, Rui Chang, Shih-Jen Chang, Lei Chang, Qianyi Chen, Gang Ma, Yajing Qiu, Xiaoxi Lin

Introduction

PHACE syndrome is a neurocutaneous syndrome characterized by large facial segmental hemangiomas as the most typical manifestation. Its prevalence in East Asian is not well studied.

Methods

The retrospective study included 98 infants with facial segmental hemangiomas who underwent brain MRI/MRA, cardiac ultrasound, and ophthalmology examinations. The prevalence along with documentation of its clinical characteristics of PHACE syndrome was analyzed.

Results

Among 98 patients, 5 (5.1%) were diagnosed with “definite” PHACE, while none (0.0%) exhibited “possible” PHACE. Most patients with PHACE syndrome had 2 or more segments, of which the frontotemporal segment was most frequently involved. Structural brain anomalies were identified in two patients, four exhibited cerebrovascular anomalies, four displayed cardiovascular anomalies, and two presented ocular anomalies. Following standardized oral propranolol therapy, all patients showed significant regression. One patient received laser treatment for a residual hemangioma.

Conclusion

The prevalence of PHACE syndrome in facial segmental hemangiomas was 5.1%, predominantly characterized by anomalies in the cerebrovascular and cardiovascular systems. Collaborative multidisciplinary diagnosis and treatment are critical for PHACE patients.

PHACE综合征是一种以面部大节段血管瘤为最典型表现的神经皮肤综合征。它在东亚的流行情况还没有得到很好的研究。方法对98例面节段性血管瘤患儿行脑MRI/MRA、心脏超声及眼科检查进行回顾性研究。分析了PHACE综合征的流行情况及临床特点。结果98例患者中,5例(5.1%)诊断为“明确”PHACE, 0例(0.0%)诊断为“可能”PHACE。大多数PHACE综合征患者有2个或更多节段,其中额颞节最常受累。脑结构异常2例,脑血管异常4例,心血管异常4例,眼部异常2例。经标准化口服心得安治疗后,所有患者均出现明显的消退。一名患者接受了残留血管瘤的激光治疗。结论面节段性血管瘤中PHACE综合征的发生率为5.1%,以脑血管、心血管系统异常为主。多学科合作的诊断和治疗对PHACE患者至关重要。
{"title":"The Prevalence and Clinical Characteristics of PHACE Syndrome in Facial Segmental Hemangiomas: A Single-Center Retrospective Study","authors":"Jingjing Sun,&nbsp;Rui Chang,&nbsp;Shih-Jen Chang,&nbsp;Lei Chang,&nbsp;Qianyi Chen,&nbsp;Gang Ma,&nbsp;Yajing Qiu,&nbsp;Xiaoxi Lin","doi":"10.1155/dth/4078903","DOIUrl":"https://doi.org/10.1155/dth/4078903","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>PHACE syndrome is a neurocutaneous syndrome characterized by large facial segmental hemangiomas as the most typical manifestation. Its prevalence in East Asian is not well studied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The retrospective study included 98 infants with facial segmental hemangiomas who underwent brain MRI/MRA, cardiac ultrasound, and ophthalmology examinations. The prevalence along with documentation of its clinical characteristics of PHACE syndrome was analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 98 patients, 5 (5.1%) were diagnosed with “definite” PHACE, while none (0.0%) exhibited “possible” PHACE. Most patients with PHACE syndrome had 2 or more segments, of which the frontotemporal segment was most frequently involved. Structural brain anomalies were identified in two patients, four exhibited cerebrovascular anomalies, four displayed cardiovascular anomalies, and two presented ocular anomalies. Following standardized oral propranolol therapy, all patients showed significant regression. One patient received laser treatment for a residual hemangioma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The prevalence of PHACE syndrome in facial segmental hemangiomas was 5.1%, predominantly characterized by anomalies in the cerebrovascular and cardiovascular systems. Collaborative multidisciplinary diagnosis and treatment are critical for PHACE patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4078903","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ficus carica Tree Latex is Used for Treating Warts: Is it a Coincidence or a New Point of View? 无花果树乳胶用于治疗疣:这是巧合还是一个新的观点?
IF 3.4 4区 医学 Q1 DERMATOLOGY Pub Date : 2025-11-23 DOI: 10.1155/dth/8490505
Mobina Rahnama, Fatemeh Hajilou, Hadis Nasoori, Naser-Aldin Lashgari

Background

Warts are common skin growths, viral in origin. In fact, many infections arise from members of the human papillomavirus (HPV) family. Traditional treatments for warts have existed to date, but all such procedures can be expensive, invasive, painful, and sometimes ineffective. Recently, there has been growing interest in remedies that can be considered alternatives to mainstream treatments.

Aim of the study

This review discusses the complementary and alternative medicinal (CAM) properties that are gaining popularity as a therapeutic approach, of the Ficus carica (fig) tree latex, its possible modes of action against warts, and anecdotal evidence about its effectiveness.

Method

Data were obtained from clinical and animal studies published in English between 1997 and September 2025 and collected from Google Scholar, PubMed, Scopus, and the Cochrane Library.

Results

F. carica latex contains proteolytic enzymes (ficins) that digest keratin and destroy the hyperkeratotic structure of warts, exposing infected tissue to immune clearance. In addition, polyphenols and flavonoids provide antioxidant and anti-inflammatory effects, while furocoumarins such as psoralen and bergapten exert antiviral and phototoxic actions that inhibit viral replication within wart tissue. While individual results may vary, many users report a reduction in the wart size or a complete clearance.

Conclusion

F. carica (fig) tree latex can be introduced as a novel treatment for cutaneous warts. Further studies are needed for the establishment of a standardized treatment approach, assessment of long-term efficacy, and elucidation of the exact mechanisms of action of F. carica latex.

疣是常见的皮肤生长,起源于病毒。事实上,许多感染是由人乳头瘤病毒(HPV)家族成员引起的。迄今为止,疣的传统治疗方法已经存在,但所有这些方法都是昂贵的,侵入性的,痛苦的,有时是无效的。最近,人们对替代主流疗法的疗法越来越感兴趣。本综述讨论了作为一种治疗方法越来越受欢迎的无花果树乳胶的补充和替代药物(CAM)特性,其对疣的可能作用模式,以及关于其有效性的轶事证据。方法数据来源于1997年至2025年9月间发表的英文临床和动物研究,收集自谷歌Scholar、PubMed、Scopus和Cochrane Library。结果乳剂含有蛋白水解酶(ficins),可消化角蛋白并破坏疣的过度角化结构,使感染组织暴露于免疫清除。此外,多酚和类黄酮具有抗氧化和抗炎作用,而呋喃香豆素(如补骨脂素和草甲素)具有抗病毒和光毒性作用,可抑制疣组织内的病毒复制。虽然个别结果可能有所不同,但许多用户报告疣大小减少或完全清除。结论无花果树乳剂可作为治疗皮肤疣的一种新方法。需要进一步的研究来建立标准化的治疗方法,评估长期疗效,并阐明牛乳杆菌的确切作用机制。
{"title":"Ficus carica Tree Latex is Used for Treating Warts: Is it a Coincidence or a New Point of View?","authors":"Mobina Rahnama,&nbsp;Fatemeh Hajilou,&nbsp;Hadis Nasoori,&nbsp;Naser-Aldin Lashgari","doi":"10.1155/dth/8490505","DOIUrl":"https://doi.org/10.1155/dth/8490505","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Warts are common skin growths, viral in origin. In fact, many infections arise from members of the human papillomavirus (HPV) family. Traditional treatments for warts have existed to date, but all such procedures can be expensive, invasive, painful, and sometimes ineffective. Recently, there has been growing interest in remedies that can be considered alternatives to mainstream treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim of the study</h3>\u0000 \u0000 <p>This review discusses the complementary and alternative medicinal (CAM) properties that are gaining popularity as a therapeutic approach, of the <i>Ficus carica</i> (fig) tree latex, its possible modes of action against warts, and anecdotal evidence about its effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Data were obtained from clinical and animal studies published in English between 1997 and September 2025 and collected from Google Scholar, PubMed, Scopus, and the Cochrane Library.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>F. carica</i> latex contains proteolytic enzymes (ficins) that digest keratin and destroy the hyperkeratotic structure of warts, exposing infected tissue to immune clearance. In addition, polyphenols and flavonoids provide antioxidant and anti-inflammatory effects, while furocoumarins such as psoralen and bergapten exert antiviral and phototoxic actions that inhibit viral replication within wart tissue. While individual results may vary, many users report a reduction in the wart size or a complete clearance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>F. carica</i> (fig) tree latex can be introduced as a novel treatment for cutaneous warts. Further studies are needed for the establishment of a standardized treatment approach, assessment of long-term efficacy, and elucidation of the exact mechanisms of action of <i>F. carica latex</i>.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8490505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145625926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatologic Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1